背景:延迟性肌肉酸痛(DOMS),也称为运动诱发的肌肉损伤(EIMD),通常是由剧烈和/或不习惯的体育锻炼引起的。DOMS/EIMD表现为肌肉力量和性能水平降低,增加肌肉酸痛,肿胀,和炎症生物标志物水平升高。许多随机对照试验(RCT)和系统评价(SRs)的各种物理治疗干预措施,以减少DOMS/EIMD的体征和症状已经发表。然而,这些SR经常得出矛盾的结论,阻碍决策过程。
目的:我们将系统回顾当前关于临床结局的证据(疗效,安全性)的物理治疗干预措施,用于治疗健康成人的DOMS/EIMD。我们也会评估证据的质量,地图,并汇总可用SR的数据。
方法:带有证据图和荟萃分析的伞综述。MEDLINE,Embase,Cochrane系统评价数据库,Epistemonikos和PEDro将从1998年1月至2024年2月进行搜索。物理治疗师使用的任何治疗的随机对照试验(例如,低水平激光治疗,电刺激,热/冷疗,超声,磁铁,按摩,手动疗法)在健康成年人中治疗DOMS/EIMD将符合资格。叙事/非系统审查,对青少年/儿童和医学受损个体的研究,补充疗法,饮食,营养,或药物干预,以及自我管理的干预措施,或1998年以前出版的,将被排除在外。AMSTAR2将用于评估所包含SRs的方法学质量。修正的覆盖区域,将计算用于评估包含的SR之间的重叠,并将准备一份证据图,以描述在相关SR中分析的干预措施的证据的可信度。
结论:DOMS/EIMD是一个复杂的条件,对于临床/理疗护理标准尚无共识。通过批判性地评估现有证据,我们的目标是告知临床医生关于DOMS/EIMD最有希望的治疗方法.这项总括审查有可能找出现有证据基础中的差距,为未来的研究提供信息。该协议已在PROSPERO注册(CRD42024485501]。
BACKGROUND: Delayed onset muscle soreness (DOMS), also known as exercise-induced muscle damage (EIMD), is typically caused by strenuous and/or unaccustomed physical exercise. DOMS/EIMD manifests itself in reduced muscle strength and performance levels, increased muscle soreness, swelling, and elevated levels of inflammatory biomarkers. Numerous randomised controlled trials (RCTs) and systematic reviews (SRs) of a wide variety of physiotherapy interventions for reducing the signs and symptoms of DOMS/EIMD have been published. However, these SRs often arrive at contradictory conclusions, impeding decision-making processes.
OBJECTIVE: We will systematically review the current evidence on clinical outcomes (efficacy, safety) of physiotherapy interventions for the treatment of DOMS/EIMD in healthy adults. We will also assess the quality of the evidence and identify, map, and summarise data from the available SRs.
METHODS: Umbrella review with evidence map and meta-meta-analyses. MEDLINE, Embase, Cochrane Database of Systematic Reviews, Epistemonikos and PEDro will be searched from January 1998 until February 2024. SRs of RCTs of any treatment used by physiotherapists (e.g., low-level laser therapy, electrical stimulation, heat/cold therapy, ultrasound, magnets, massage, manual therapies) to treat DOMS/EIMD in healthy adults will be eligible. Narrative/non-systematic reviews, studies of adolescents/children and medically compromised individuals, of complementary therapies, dietary, nutritional, or pharmacological interventions, as well as self-administered interventions, or those published before 1998, will be excluded. AMSTAR 2 will be used to evaluate the methodological quality of the included SRs. Corrected covered area, will be computed for assessing overlaps among included SRs, and an evidence map will be prepared to describe the credibility of evidence for interventions analysed in the relevant SRs.
CONCLUSIONS: DOMS/EIMD is a complex condition, and there is no consensus regarding the standard of clinical/physiotherapeutic care. By critically evaluating the existing evidence, we aim to inform clinicians about the most promising therapies for DOMS/EIMD. This umbrella review has the potential to identify gaps in the existing evidence base that would inform future research. The protocol has been registered at PROSPERO (CRD42024485501].